Gamma delta (gd) T cells have gained attention as cells with immunotherapy potential in the cancer field. Gd T cells are different from conventional alpha beta T cells in their development, receptor and activation pathways. Since gd T cells do not require MHC class I molecules on target cells to be activated and neuroblastoma tumor cells express low to no MHC class, this subtype of T cells appears as a very interesting cell type to study in this disease. In our project we are analyzing gd T cells from neuroblastoma samples and animal models obtained from publicly available and already preprocessed data to find possible new antigens on neuroblastoma tumor cells that can be exploited for novel therapeutics.